A new study conducted by researchers at the Universidad Nacional Autónoma de México in Mexico recently revealed new insights into the mechanisms underlying motor neuron degeneration, offering potential new treatment strategies for amyotrophic lateral sclerosis (ALS). The study is entitled “Degeneration of spinal motor neurons by…
New Insights Into Motor Neuron Degeneration and Potential ALS Therapies
A new study led by researchers at the Mayo Clinic and recently published in the journal Science reported a new, important mouse model that allows the study of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, two relevant neurodegenerative diseases. The study is entitled “…
French pharmaceutical company AB Science SA has organized a web conference to present information on its lead product for the treatment of amyotrophic lateral sclerosis (ALS), a drug therapy called masitinib. The seminar held by AB Science, which is specialized in developing and commercializing protein…
The Annual Drug Company Working Group and the American Academy of Neurology (AAN) meetings were recently held by the ALS Association last month in Washington, D.C. with main focus on amyotrophic lateral sclerosis (ALS). The association is now sharing the most important data presented at the…
May is Awareness Month for amyotrophic lateral sclerosis (ALS). The ALS Association is celebrating this year in hopes of topping the huge awareness that was generated last summer through the ALS Ice Bucket Challenge and the incredibly enormous impact it had on the fight against the disease. To continue the momentum, The Association…
BrainStorm Cell Therapeutics Inc. has presented promising results on the Phase 2a clinical trial of its product NurOwn® for amyotrophic lateral sclerosis (ALS) at the 67th American Academy of Neurology Annual Meeting, which took place this year in Washington D.C from April 18-25. The presented poster was entitled…
In a new study entitled “Phase I Trial of Repeated Intrathecal Autologous Bone Marrow-derived Mesenchymal Stromal Cells in Amyotrophic Lateral Sclerosis,” researchers performed a safety study with stem cells based therapy to treat Amyotrophic Lateral Sclerosis patients and concluded it as a safe and promising therapy. The…
AB Science SA, a pharmaceutical company focused on research, development and marketing of protein kinase inhibitors (PKIs), has announced that it is hosting a web conference including key opinion leaders and experts covering its experimental therapy masitinib and its utility to treat amyotrophic lateral sclerosis (ALS). The web conference call will be held from 5:35…
A research team from Pitié–Salpêtrière Hospital in Paris found major structural alterations of the neuromuscular junctions (NMJs) in early stage Amyotrophic Lateral Sclerosis (ALS) patients. The study entitled “Endplate denervation correlates with Nogo-A muscle expression in amyotrophic lateral sclerosis patients” was published April 2015 in…
A researcher from Baltimore is going to receive $130,000 to support her research on the most frequent subtype of familial amyotrophic lateral sclerosis (ALS); the funds come from the Clinical Research Training Fellowship in ALS, co-sponsored by the ALS Association and American Brain Foundation. The award was presented during the largest meeting of…
Recent Posts
- Dazucorilant shows significant survival benefit in Phase 2 ALS trial
- Seeking to harness ‘real momentum’ is goal of this year’s ALS Awareness Month
- How I stimulate my mind while caring for my husband with ALS
- Developer gets OK to expand first-in-human trial of ALS therapy to Europe
- Out-of-pocket ALS costs create heavy financial burden for French families